Relieves discomfort associated with acute, painful musculoskeletal conditions. ANDA 205126, held by Heritage. Carisoprodol.
As of Nov 16, 2026, ANDA 205126 (Carisoprodol), held by Heritage, was first approved by FDA on Jul 8, 2015, with 3 approved supplements and 0 published complete response letters.
Carisoprodol Tablets, USP are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 8, 2015 | Original application | Approved | None posted |
| Carisoprodol250MG · tablet;oral | Carisoprodol | Rx |
| Carisoprodol350MG · tablet;oral | Carisoprodol | Rx |
| Apr 28, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 13, 2018 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 31, 2017 | Supplement 2Manufacturing | Approved | None posted |
| Jul 8, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters